EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Global Health Ltd (GLH) fair value: what the stock is really worth

As of Oct 2, 2026: fair value of Global Health Ltd A$0.07, price A$0.06, upside +11.7%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? Yes
  2. Good quality? Yes
  3. Add to watchlist

Healthcare · AU · ISIN AU000000GLH2

GH Thin data Sep 13, 2026

Global Health Ltd

GLH · AU

UndervaluedThe stock appears undervalued with acceptable quality.

✓Fair value A$0.0682 · Undervalued (+11.7%)
!Quality 57/100
!Expensive Growth (revenue 5y +7.7 %/yr)
!Loss-making · -9.6% net margin (TTM)
!Negative equity (buybacks among others) · negative free cash flow
!Trails peers (3/8)
!Narrow moat 8/100
!Evidence only low, so the estimate is less certain
Watch Global Health Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

A$0.5250 A$0.0480 Fair Value A$0.0682 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.

How to read this chart

60‑month range A$0.0480 – A$0.5250 · fair‑value band A$0.0490 – A$0.0970 · the A$0.0610 price screens below the A$0.0682 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. Dashed = 300-day average. As of Sep 13, 2026.

Follow Global Health in your weekly email

Every Wednesday you see whether Global Health is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Global Health Limited provides digital health solutions for the healthcare industry in Australia.

Show more

Global Health Limited provides digital health solutions for the healthcare industry in Australia. The company offers software as a service platform and software applications for electronic medical records, client management systems, patient administration systems, practice management systems, clinical records, secure messaging, patient engagement platforms, and consumer health records. It is also involved in the development, sale, and support of the application software for the healthcare sector; and development of system integration software that enables data to be exchanged within an enterprise. The company sells its products under the MasterCare, PrimaryClinic, HotHealth, ReferralNet, and Lifecard brands. Global Health Limited was founded in 1985 and is headquartered in Melbourne, Australia.

Stock analysis

Global Health Ltd (GLH) currently trades at A$0.0610, while our model-based Fair Value estimate is A$0.0682, implying the stock looks roughly 10.5% undervalued today.

Show more

Valuation

How firm this estimate is: it rests on 2 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: A$0.0490 (bear) to A$0.0970 (bull), the price of A$0.0610 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Global Health Ltd reported revenue of A$8.7M in FY2025 versus A$7.0M in FY2021, a compound +5.4%/yr. Reported net income was −A$867K in FY2025.

Key figures

Market cap A$3.6M (≈ $2.5M) · P/S ratio 0.45 · EPS (TTM) A$−0.0100 · Net margin −10.0% · Return on equity −1,359% · Return on assets (EBIT) −44.5% · Operating margin −9.9% · Revenue (TTM) A$8.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (low confidence).

What moves the price

The share trades about 42% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 6% fair-value upside, at 12%, GLH screens cheaper than that median.

Notify me when GLH reaches fair value

Put GLH on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 57/100

Of which business quality 56 · Market factors (momentum, volatility) 31

Profitability 50
Margins and returns on capital today
Quality Growth 88
Are margins and returns improving?
Cashflow 30
Earnings quality: real cash, not paper profit
Fin. Strength 33
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 26
Price trend over the last 3–12 months (market factor)
52W Momentum 11
Distance to the 52-week high (market factor)
Net Issuance 74
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+6.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.9%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Start year 2020 (pandemic). Over 10 years: +8.2% a year
Revenue growth 24 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
1.4% (2020) → −9.2% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch GLH, get fair value alerts →

Compare Global Health Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 128 stocks

Beats the industry median on 3/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 56 · Above median
Fair Value upside −67.7% · Below median
Profitability
Return on equity (TTM) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −20.8% · Bottom 25%
Net margin (TTM) −9.6% · Below median
Operating margin (TTM) −9.9% · Below median
Growth and dividend
Revenue growth −4.7% · Bottom 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (TTM) 0.29× · Cheapest 25%
PEG 1.27× · Cheaper than median

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $278.57 $306.43 +10%
Pro Medicus Limited PME A$161.00 A$84.62 −47%
BrightSpring Health Services, Inc BTSG $56.54 $25.86 −54%
Hinge Health, Inc HNGE $95.57 $51.25 −46%
HealthEquity, Inc HQY $88.44 $97.28 +10%
Waystar Holding WAY $24.70 $27.17 +10%
Doximity, Inc DOCS $26.35 $31.41 +19%
XtalPi Holdings 2228 HK$7.75 HK$1.50 −81%
Inventurus Knowledge Solutions Limited IKS ₹1,779 ₹1,883 +6%
Privia Health Group PRVA $19.62 $5.02 −74%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Global Health Ltd · Fair Value
A$0.0682 +11%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Global Health Ltd Fair Value". https://www.fairvalue-calculator.com/stock/GLH

Frequently asked questions

Is Global Health Ltd (GLH) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of A$0.0682 versus a price of A$0.0610, about +12% upside (undervalued).
What is the fair value of GLH?
Our model-based fair value for Global Health Ltd is A$0.0682 (as of Sep 13, 2026), built from audited fundamentals. The current price: A$0.0610.
What is the quality score of GLH?
Global Health Ltd has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Global Health Ltd (GLH)?
Our model-based price target is the fair value of A$0.0682 (as of Sep 13, 2026) from 2 valuation models. Cautious scenario A$0.0490, optimistic scenario A$0.0970. It is a calculation from audited fundamentals, not an analyst target.
What is the Global Health Ltd stock forecast for 2026?
Our models put fair value at A$0.0682, about +12% upside versus a price of A$0.0610 (undervalued). Cautious scenario A$0.0490, optimistic scenario A$0.0970. The calculation is refreshed regularly with new filings.
What is the revenue of Global Health Ltd (GLH)?
Global Health Ltd reported trailing-twelve-month revenue of about A$8.5M (latest available figure, as of Sep 13, 2026).
What is the intrinsic value of Global Health Ltd (GLH)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Global Health Ltd it is A$0.0682 per share (as of Sep 13, 2026), against a price of A$0.0610. It is the blended result of 2 valuation models (cash flow, earnings, asset, dividend).
Is Global Health Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, GLH trades below its calculated fair value: price A$0.0610, fair value A$0.0682, a gap of about +12% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of GLH?
No. The price is what the market pays today (A$0.0610); the fair value is what the company's own numbers justify (A$0.0682). For Global Health Ltd the two are A$0.0072 per share apart. That gap is exactly why we show both numbers side by side.
How much is Global Health Ltd worth?
The market values Global Health Ltd at about A$3.6M (market capitalisation, as of Sep 13, 2026). Per share that is A$0.0610; our models calculate a fair value of A$0.0682 per share.
What do the bullish and bearish scenarios say about GLH?
Our models span a range for Global Health Ltd: cautious scenario A$0.0490, base A$0.0682, optimistic A$0.0970 per share (as of Sep 13, 2026, price A$0.0610). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of GLH?
The PEG ratio of Global Health Ltd is 1.27 (P/E divided by earnings growth, as of Sep 13, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Global Health Ltd (GLH)?
Balance-sheet figures for Global Health Ltd (as of Sep 13, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is GLH from its 52-week high?
Global Health Ltd trades at A$0.0610, about 42% below its 52-week high of A$0.1050 and 27% above the low of A$0.0480 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of A$0.0682 is for.
Which stocks are comparable to Global Health Ltd?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Hinge Health, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Global Health Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price A$0.0610, calculated fair value A$0.0682 (+12%), Quality Score 57/100, from 2 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of GLH calculated?
We run Global Health Ltd through 2 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of A$0.0682, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Global Health Ltd currently trades 11 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Global Health Ltd (GLH)?
The closing price on Oct 2, 2026 was A$0.0610. Our model-based fair value is A$0.0682, about +12% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Global Health Ltd right now?
A fairly wide model range (A$0.0490 to A$0.0970) leaves room in how you read the outcome. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Global Health Ltd

How large is the market capitalisation of Global Health Ltd (GLH)?
The market capitalisation of Global Health Ltd is A$3.6M (≈ $2.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Global Health Ltd (GLH)?
The price-to-sales ratio of Global Health Ltd is 0.45 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Global Health Ltd (GLH)?
Earnings per share at Global Health Ltd are A$−0.0100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Global Health Ltd (GLH)?
The net margin of Global Health Ltd is −10.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Global Health Ltd (GLH)?
The return on equity (ROE) of Global Health Ltd is −1,359% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Global Health Ltd (GLH)?
On an EBIT basis the return on assets of Global Health Ltd is −44.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Global Health Ltd (GLH)?
The operating margin of Global Health Ltd is −9.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Global Health Ltd (GLH)?
Revenue at Global Health Ltd is growing −4.7% versus a year earlier (3y avg +9.9%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Global Health Ltd (GLH) generate?
The free cash flow of Global Health Ltd is −A$707K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Global Health Ltd (GLH) carry?
The net debt of Global Health Ltd is A$77.7K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Global Health Ltd in the live analysis

One click puts Global Health Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.